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OBJECTIVES The purpose of this study was to compare the clinical and echocardiographic features of adults
who developed atrial tachyarrhythmias (ATs) late after a Fontan procedure with those who
have remained free of arrhythmias.
BACKGROUND Atrial tachyarrhythmias are a frequent complication of the Fontan operation. However, the
outcomes in adult patients with AT who have had the Fontan operation have not been well
defined.
METHODS We reviewed the outcomes of 94 consecutive patients who underwent the Fontan operation
between 1977 and 1994 and were followed as adults at the University of Toronto Congenital
Cardiac Centre for Adults. Sixty patients had an atriopulmonary connection, 21 patients had
an atrioventricular connection, and 13 patients received a lateral tunnel connection.
RESULTS Thirty-nine patients (41%) had sustained AT (atrial fibrillation, atrial flutter or supraven-
tricular tachycardia) after their Fontan procedure. Compared with patients who did not
develop AT, those who did were more likely to develop heart failure (46% vs. 13%, p 5 0.003)
and right atrial thrombus (31% vs. 4%, p 5 0.006), exhibit left atrial enlargement (mean
[6SD] diameter: 44 6 10 vs. 37 6 9 mm, p 5 0.002), exhibit right atrial enlargement (mean
[6SD] volume: 139 6 149 vs. 76 6 54 ml, p 5 0.040) and have moderate-to-severe systemic
valve regurgitation (31% vs. 7%, p 5 0.010). The mean survival time was not significantly
different between the arrhythmia group and the arrhythmia-free group (21.2 6 1.3 and
18.0 6 0.7 years, respectively; p 5 0.900).
CONCLUSIONS Systemic atrioventricular valvular regurgitation and biatrial enlargement are commonly
observed in patients who develop AT after the Fontan procedure. These patients are more
likely to develop right atrial thrombus and heart failure. (J Am Coll Cardiol 2001;37:585–92)
© 2001 by the American College of Cardiology
The Fontan operation is a well-established surgical proce-
dure for the palliation of patients with complex cyanotic
congenital heart defects such as tricuspid atresia, pulmonary
atresia and double-inlet ventricle (1). Studies examining
mostly pediatric patients have reported atrial tachyarrhyth-
mias (ATs) in up to 57% after they had the Fontan
procedure (2–9). Preliminary results from a multicenter,
retrospective study of adults with Fontan physiology also
reported that 49% of their patient group developed AT (10).
A number of risk factors for the development of late AT
have been described, including poor preoperative functional
class, previous atrial septectomy, preoperative AT, age at
operation, the need for atrioventricular valve replacement,
pulmonary artery (PA) reconstruction, right atrium (RA) to
PA Fontan connection, early postoperative AT, postopera-
tive sinus node dysfunction and length of follow-up
(6,8,9,11,12).
Although these risk factors have been well described, the
relation between the development of AT and subsequent
clinical outcomes has not been well defined. In view of the
reported incidence of AT after the Fontan procedure, it is
important to relate the development of AT to other clinical
outcomes such as heart failure, atrial thrombosis, pulmonary
embolism, protein-losing enteropathy and death (4,7,9,
13,14). The purpose of this study was to compare the
clinical and echocardiographic features of adults who devel-
oped late AT with those who have remained free of
arrhythmias.
METHODS
Patients. Adults ($18 years old) who had a previous
Fontan procedure, as identified from the University
of Toronto Congenital Cardiac Centre for Adults
(UTCCCA) computerized data base, were assessed there
between June 1985 and September 1997. Patients at
UTCCCA are followed according to standardized schedul-
ing templates for clinic visits and cardiac investigations. For
example, patients who have had the Fontan procedure
undergo 12-lead electrocardiography and transthoracic
echocardiography at the time of their annual clinic visit. The
purpose of this study was to examine late outcomes; there-
fore, patients who did not survive beyond 30 days after the
initial Fontan procedure were excluded. Baseline informa-
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tion, including demographic data, cardiac anatomy and
operative reports, was obtained from a review of the pa-
tient’s medical records. Any clinical events that occurred
after the patient’s initial Fontan operation, including heart
failure, cardiac thrombus, pulmonary embolus, protein-
losing enteropathy, cardiac reoperation and death, were
recorded. Follow-up data were updated to December 31,
1997. The majority of patients in our data base were
followed annually (n 5 75 of 94) at the UTCCCA.
Nineteen patients were not seen at UTCCCA during 1997,
because they were followed by other centers of the Canadian
Adult Congenital Heart (CACH) Network; member cen-
ters of the CACH network utilize the same standardized
follow-up template as UTCCCA. The most recent
follow-up information on these 19 patients was obtained
from their local CACH center. The research Ethics Board
of the Toronto General Hospital approved this study.
Definitions. Cardiac anatomy was reviewed, and the prin-
cipal lesion was defined as either tricuspid atresia or uni-
ventricular connection. The latter group included patients
with a double-inlet left ventricle or right ventricle (RV).
Fontan procedures were divided into three categories: atrio-
ventricular connection (right atrial to right ventricular [RA-
RV]), atriopulmonary connection (RA-PA) or lateral tunnel
variant of total cavopulmonary connection (TCPC).
Atrial tachyarrhythmias included any sustained episode of
atrial flutter, atrial fibrillation or supraventricular tachycar-
dia occurring at least 30 days after the patient’s Fontan
operation. Patients with no evidence of sustained AT before
and at least 30 days after their Fontan operation were
deemed to be “arrhythmia-free.”
Data from the patient’s most recent transthoracic echo-
cardiogram were used to determine systemic ventricular
systolic function, the degree of systemic atrioventricular
valve regurgitation (AVVR) and atrial size. Echocardiogra-
phy was performed by an experienced research sonographer
who had no knowledge of the patients’ clinical data; an
experienced echocardiographer (Dr. Siu) confirmed the
sonographer’s assessments. Systolic function of the systemic
ventricle on echocardiography was semiquantitatively as-
sessed as normal to mildly impaired (estimated ejection
fraction .40%) or moderately to severely impaired (,40%)
(15). The magnitude of AVVR was also classified as either
none/mild or moderate/severe using color flow Doppler
criteria (16,17). Left atrial (LA) dimension was measured
from the parasternal long-axis view. The maximal medio-
lateral or superoinferior RA dimensions were measured
from the apical four-chamber view at end-systole. Right
atrial volume was calculated using a validated prolate ellip-
soid formula (18). Right atrial volumes were not assessed in
patients with TCPC, because of the presence of the lateral
tunnel.
Statistical analysis. Data were presented as the mean
value 6 SD; the median value and range were given if the
data were not normally distributed. Patients were classified
into two groups based on the occurrence of AT. A baseline
comparison between the two groups was performed. Con-
tinuous variables were compared by using the Wilcoxon
rank-sum test. Categoric variables were compared by using
the chi-square or Fisher exact test, as appropriate. The
proportion of patients with clinical events in the two groups
was compared by log-rank analyses. The level of significance
was set at p , 0.05 (two-sided). Survival for both groups
was demonstrated by the Kaplan-Meier method. The pre-
dictive role of gender, age at Fontan procedure, develop-
ment of late AT, original cardiac lesion and type of repair on
mortality was examined using Cox proportional hazard
regression analysis utilizing a stepwise backwards elimina-
tion algorithm (level of significance set at p , 0.05).
RESULTS
Patients. One hundred and thirteen patients were identi-
fied as having undergone a Fontan procedure. Nineteen
patients were excluded from the study: 6 of these patients
died from postoperative complications within 30 days after
their Fontan operation and 13 were lost to follow-up. The
study group comprised 94 patients (47 males, 47 females).
There were 39 patients (41%) in the AT group and 55
patients (59%) in the arrhythmia-free group (Table 1); no
patients in the arrhythmia-free group developed AT in the
early postoperative period (within 30 days after the Fontan
procedure). The principal cardiac lesion was tricuspid atre-
sia. A significantly higher proportion of patients in the
arrhythmia group had previous transposition of the great
arteries, compared with the arrhythmia-free group. The
Blalock-Taussig and Glenn shunts were the most common
palliative procedures preceding the Fontan operation. Ap-
proximately 19% of patients had no palliative cardiovascular
operation before their Fontan procedure. The majority
(64%) of patients in this study had a RA-PA connection.
The remaining patients received either a RA-RV conduit
(22%) or TCPC (14%). A greater proportion of patients in
the AT group received a RA-PA connection, compared
with those in the arrhythmia-free group.
The age range for all patients at the time of their Fontan
operation was 5 to 40 years. Follow-up to the last year of the
study was available for 92 (98%) of the 94 patients.
Postoperative follow-up for all patients who had the Fontan
Abbreviations and Acronyms
AT 5 atrial tachyarrhythmia
AVVR 5 atrioventricular valvular regurgitation
CACH 5 Canadian Adult Congenital Heart
LA 5 left atrium
PA 5 pulmonary artery
RA 5 right atrium
RV 5 right ventricle
TCPC 5 total cavopulmonary connection
UTCCCA 5 University of Toronto Congenital Cardiac
Centre for Adults
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operation ranged from 2 to 20 years (mean 11). Ninety
percent (84 of 94), 65% (61 of 94) and 15% (14 of 94) of our
patients were followed for 5, 10 and .15 years, respectively,
after the Fontan operation. The mean postoperative
follow-up periods for the AT group and the arrhythmia-free
group were 12 and 10 years, respectively. The mean age of
all patients during their last clinic visit was 28 years. The
average ages for the AT group and arrhythmia-free group
during their last clinical visit were 31 and 26 years, respec-
tively.
Type and clinical presentation of late AT. Thirty-nine
patients (41%) developed late AT. Six of these patients
developed AT in the early postoperative period (within 30
days of the Fontan procedure) and redeveloped the same
type of arrhythmia in the late postoperative period (atrial
flutter in five and supraventricular tachycardia in one).
The average age of onset of late AT was 26 years. The
number of patients presenting with their first episode of AT
in the age ranges of 5–9, 10–14, 15–19, 20–24, 25–29,
30–34, 35–40 and 41–45 years was 1, 3, 7, 7, 9, 4, 6 and 2,
respectively. Patients developed their AT a mean duration
of seven years after their Fontan procedure. Symptoms were
present in 25 (64%) of 39 patients during their first
presentation of arrhythmia and included palpitations (62%),
fatigue (44%), dyspnea (23%), edema (21%), presyncope
(21%) and syncope (3%). Eight of these patients (21%) first
presented to an emergency ward; another nine patients first
presented to their family physician; and eight patients
developed their AT during their hospital stay. Fourteen
patients were asymptomatic; their AT was detected during
routine cardiology assessment.
Atrial fibrillation alone was observed in 12 (31%) of 39
patients, atrial flutter alone in 9 patients (23%) and other
ATs in 15% of patients. The remaining 31% of patients in
the arrhythmia group developed a combination of atrial
flutter, atrial fibrillation and/or other atrial arrhythmias.
The clinical (age at follow-up and age at the Fontan
operation) and echocardiographic (atrial volume, moderate
to severe AVVR or systemic systolic ventricular function)
characteristics of the patients experiencing atrial flutter
alone and atrial fibrillation alone were not significantly
different. However, the small sample size (atrial fibrillation,
n 5 12; atrial flutter, n 5 9) precludes further interpreta-
tion.
Two patients developed AT before, and continued to
have arrhythmias, after their Fontan operation. Atrial tachy-
arrhythmia was chronic in 9 (23%) of the 39 patients and
recurrent in 22 patients (56%). The remaining 21% of
patients in the AT group had only one episode of docu-
mented AT during the study period. For those patients (n 5
8) with only one episode of postoperative AT, the age at
onset of the arrhythmia was 26 6 7 years (range 17 to 38)
at an interval of 8 6 7 years (range 1.5 to 22.5) after the
Fontan procedure.
Ten patients (26%) who developed AT received pace-
makers, whereas 30 (77%) of the 39 patients were managed
with antiarrhythmic medications, including propafenone,
procainamide, sotalol, digoxin and amiodarone.
Table 1. Baseline Characteristics of the Arrhythmia and Arrhythmia-Free Groups
Arrhythmia Group
(n 5 39)
Arrhythmia-Free
Group (n 5 55)
p
Value
Male 24 (62) 23 (42) 0.060
Congenital anatomy
Atrial septal defect 31 (79) 49 (89) 0.198
Ventricular septal defect 25 (64) 42 (76) 0.196
Pulmonary stenosis 25 (64) 44 (80) 0.086
Aortic stenosis 4 (10) 2 (4) 0.196
Transposition of great arteries 23 (59) 19 (35) 0.019
Hypoplastic ventricle 13 (33) 21 (38) 0.630
Tricuspid atresia 26 (67) 28 (51) 0.128
Univentricular connection 13 (33) 27 (49) 0.128
Fontan type
RA-PA connection 31 (80) 29 (53) 0.025
RA-RV connection 6 (15) 15 (27) —
TCPC connection 2 (5) 11 (20) —
Other operations
Blalock-Taussig shunt 19 (49) 30 (55) 0.577
Waterston shunt 4 (10) 3 (5) 0.382
Potts shunt 8 (21) 8 (15) 0.448
Glenn shunt 18 (46) 25 (45) 0.947
Atrial septal defect repair 24 (62) 32 (58) 0.744
Ventricular septal defect repair 11 (28) 16 (29) 0.925
Fontan conduit repair 7 (18) 9 (16) 0.840
Pacemaker implantation 10 (26) 3 (5) 0.005
Mean age (years) at Fontan operation 19 6 9 16 6 8 0.060
Median age (years) at Fontan operation 16 15 0.100
Data are presented as number (%) of patients, except for mean (6SD) age.
PA 5 pulmonary artery; RA 5 right atrium; RV 5 right ventricle; TCPC 5 total cavopulmonary connection.
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Echocardiographic features. Echocardiographic data were
available for quantitation in 80 of the 94 patients. Systemic
ventricular function and AVVR could be quantitated in 74
and 75 of these patients, respectively. Twenty-six percent of
patients had a moderate to severe reduction in systolic
function of the systemic ventricle; the majority of patients
(74%) had mildly impaired to normal systemic ventricular
function. There was a trend toward a higher proportion of
patients with moderate to severely impaired systemic ven-
tricular function in the AT group (38% vs. 17% in the
arrhythmia-free group; p 5 0.060). Thirteen (17%) of the
75 patients with echocardiographic data had moderate to
severe AVVR. Moderate to severe AVVR was present in a
higher proportion of patients in the arrhythmia group
(31%), compared with those in the arrhythmia-free group
(7%; p 5 0.010). Six patients had both a moderate to severe
reduction in systolic function and moderate to severe
AVVR. Four of the six patients had an isolated episode of
AT. When these patients were arrhythmia-free, they con-
tinued to have both moderate to severe AVVR and a
moderate to severe reduction in systolic ventricular function
at the last follow-up echocardiographic study in December
1997. Two other patients had chronic AT and continued to
have both moderate to severe AVVR and systemic ventric-
ular systolic dysfunction at follow-up.
The 13 patients with moderate to severe AVVR had
significantly larger mean RA mediolateral (67 6 21 vs. 50 6
14 mm; p 5 0.009), RA superoinferior (67 6 22 vs. 52 6
15 mm; p 5 0.04) and LA dimensions (47 6 9 vs. 38 6
9 mm; p 5 0.002), compared with the 59 patients without
significant AVVR. There was no significant difference in
age at the Fontan operation and the postoperative interval
between patients with and those without hemodynamic
residua (moderate to severe systemic ventricular dysfunction
or AVVR). The group with hemodynamic residua had a
higher proportion of patients with RA-PA Fontan proce-
dures, compared with the group without these residua (80%
vs. 55%; p 5 0.017).
Quantitation of LA dimension was feasible in 76 patients
(81%) (Table 2). Measurements of RA dimension were
feasible in 64 patients. The mediolateral and superoinferior
RA dimensions exceeded the normal ranges in 80% and
75% of patients, respectively (19,20). The mean RA size and
volume were higher in patients with AT. The mean LA size
in the AT group was significantly larger than that in the
arrhythmia-free group (44 6 10 vs. 39 6 9 mm; p 5 0.002).
Statistically significant differences in RA and LA sizes
between the two groups were still present when patients
with chronic AT were excluded from the analysis.
Clinical outcomes. The frequencies of various clinical
outcomes in the arrhythmia and arrhythmia-free groups are
presented in Table 3. Of the 25 patients (27%) who
developed congestive heart failure after their Fontan oper-
ation, 18 were in the AT group (46% vs. 13% in the
arrhythmia-free group; p 5 0.003). The first episode of
heart failure occurred after the development of AT in 15 of
18 patients. Three were documented to have heart failure
before the onset of AT; two of the three patients had
recurrent heart failure after the onset of AT.
Right atrial thrombus was detected by echocardiography
in 14 patients (15%), 12 of whom were in the AT group
(p 5 0.006). Of these 12 patients, 3 had RA thrombus first
detected before the onset of AT (one had recurrence of
thrombus after AT) and 9 had RA thrombus first detected
after the onset of AT. In eight of the nine patients in whom
RA thrombus was diagnosed after the onset of AT, the
diagnosis was established in the four weeks immediately
after an episode of AT (n 5 2) or within the same hospital
Table 2. Comparison of Chamber Size Dimensions and Volume in Patients Who Have Had the Fontan Operation
Chamber
Dimension or
Volume
Type of
Fontan Procedure
Arrhythmia Group Arrhythmia-Free Group
p
Valuen
Dimension or
Volume
(mean 6 SD) n
Dimension or
Volume
(mean 6 SD)
RA-ML RA-PA or RA-RV 29 59 6 19 mm 35 49 6 13 mm 0.019
RA-SI RA-PA or RA-RV 29 60 6 18 mm 35 51 6 15 mm 0.037
RA Volume RA-PA or RA-RV 29 139 6 149 ml 35 76 6 54 ml 0.040
LA size RA-PA or RA-RV or TCPC 32 44 6 10 mm 44 37 6 9 mm 0.002
Data are presented as number (n) of patients and mean 6 SD.
LA 5 left atrial; ML 5 mediolateral; PA 5 pulmonary artery; RA 5 right atrium; RV 5 right ventricle; SI 5 superoinferior; TCPC 5 total cavopulmonary connection.
Table 3. Presence of Clinical Outcomes in Patients Who Have Had the Fontan Operation
Clinical Outcome
Arrhythmia
Group
Arrhythmia-Free
Group
p
Value
Heart failure 18 (46) 7 (13) 0.0036
Right atrial thrombus 12 (31) 2 (4) 0.0062
Pulmonary embolus 2 (5) 5 (9) 0.37
Protein-losing enteropathy 2 (5) 1 (2) 0.52
Reoperations 15 (38) 11 (20) 0.25
Death 4 (10) 5 (9) 0.090
Data are presented as the number (%) of patients.
588 Ghai et al. JACC Vol. 37, No. 2, 2001
Atrial Tachyarrhythmias in Adults With Fontan February 2001:585–92
period (n 5 6). In the remaining one patient, RA thrombus
was diagnosed at 12 months after the first documented
episode of AT. The patient had been experiencing frequent
palpitations since the initial episode of AT. As Holter
monitoring failed to capture these episodes of palpitations,
it is possible that they may represent episodes of AT.
Seven patients (7%) in the study had a documented
episode of pulmonary embolus. Five of these patients were
in the arrhythmia-free group. No significant difference was
noted between the arrhythmia and arrhythmia-free groups
with respect to the development of pulmonary embolus.
Three (17%) of the 18 patients who developed RA throm-
bus or pulmonary emboli were already receiving either
aspirin (n 5 2) or warfarin (n 5 1) at the time of diagnosis;
in the months before the diagnosis of RA thrombus, there
was difficulty maintaining adequate anticoagulation in the
one patient receiving warfarin. More patients in the ar-
rhythmia group were receiving aspirin or warfarin for either
the prevention or treatment of RA thrombus, compared
with the arrhythmia-free group (72% vs. 36%, p 5 0.008).
All patients with RA thrombus or pulmonary emboli were
placed on long-term warfarin therapy.
Three patients developed protein-losing enteropathy
(3%). No significant differences in the frequency were noted
between the arrhythmia and arrhythmia-free groups.
Twenty-six patients underwent reoperation after the
initial Fontan procedure (28%). Reoperation was required in
15 patients with arrhythmias (38%) and in 11 patients who
were arrhythmia-free (20%) (p 5 0.25). Fifteen (58%) of 26
patients underwent replacement of an obstructed Fontan
connection. In these 15 patients, the origin and insertion of
their new connection was the same as that of their original
operation (RA-RV, RA-PA and TCPC in 11, 3 and 1
patients, respectively). As of December 1997, none of these
patients had revision of a lateral tunnel or extracardiac
Fontan connection. Four of six patients who had AT before
their Fontan revision continued to have AT afterward; there
was no recurrent AT in the remaining two patients. The
other nine patients who underwent Fontan revisions did not
have AT either before or after their revision.
Another three patients (12%) had a subaortic myectomy
procedure, whereas two patients (8%) underwent heart
transplantation. Five other patients underwent reoperation
for closure of an atrial septal defect (n 5 1), ligation of a
Blalock-Taussig shunt (n 5 1), ligation of a pulmonary
arteriovenous fistula (n 5 1), ligation of a Potts shunt (n 5
1) or cryoablation in the RA for arrhythmia management
(n 5 1). One patient underwent systemic atrioventricular
valve replacement for severe regurgitation; she was in the
arrhythmia-free group. None of the patients undergoing
reoperation had PA reconstruction. No statistically signifi-
cant differences were noted regarding the type of post-
Fontan operation performed in the arrhythmia and
arrhythmia-free groups.
Nine patients in the study died beyond the immediate (30
days) postoperative period after their Fontan operation. The
time of death ranged from 2 to 15 years after the patient’s
Fontan operation. Four of the deaths were the result of
progressive myocardial failure. One patient died from a
stroke, whereas another experienced sudden death second-
ary to a presumed arrhythmia. Two deaths were from
noncardiac causes. Information regarding the cause of death
in one patient was unavailable. Multivariate Cox propor-
tional hazard analysis did not identify statistically significant
predictors of mortality. As shown in Figure 1, there was no
significant difference in mean survival time from the time of
operation between the arrhythmia and arrhythmia-free
groups (21.2 6 1.3 and 18.0 6 0.7 years, respectively; p 5
0.900). Five of the nine deaths were in the arrhythmia-free
group.
When the two patients with AT before their Fontan
procedure were excluded, the aforementioned statistically
significant difference in the proportion of patients with
heart failure and RA thrombus between the arrhythmia and
arrhythmia-free groups was still present.
DISCUSSION
Although early and late mortality have decreased for the
modified Fontan procedure, arrhythmias, heart failure,
thromboembolism and protein-losing enteropathy continue
to be a problem for this population. The present study
shows a high frequency of sustained ATs and an association
of these events with heart failure and RA thrombus.
Patients with AT were more likely to have enlarged LA and
RA size, systemic ventricular systolic dysfunction and mod-
erate to severe AVVR. However, the development of AT
did not significantly alter long-term survival during a mean
follow-up period of 11 years.
Arrhythmias. The present study demonstrates a 41% oc-
currence of late AT after the Fontan operation, a finding
consistent with previous reports (2–9). Importantly, a pre-
liminary report from a multicenter study reported an even
Figure 1. Kaplan-Meier survival curve for all-cause mortality beyond the
age of 18 years for the arrhythmia group (solid line) and the arrhythmia-
free group (dotted line). n 5 number of patients remaining in follow-up at
the corresponding time after the Fontan operation.
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higher frequency (49%) of AT (10). Compared with other
studies, our study examined adult survivors of the Fontan
procedure as well as those who underwent this operation in
adulthood. Our study also had a longer follow-up period for
a majority of the group. Approximately two-thirds of our
study group were followed for .10 years and 15% for .15
years. Other studies have demonstrated that length of
follow-up is a risk factor for the development of AT
(6,9,11). The relation between time and arrhythmia devel-
opment is presumed to be mediated by progressive RA
distention from long-standing elevation in RA pressures
(11). Because the risk of developing atrial fibrillation and
atrial flutter increases with time, it is likely there will be an
increasing number of patients who have had the Fontan
operation in whom atrial fibrillation and atrial flutter will
develop. One patient in this study developed atrial fibrilla-
tion .20 years after the Fontan operation.
Unlike other studies, ours predominantly included older
variants of the Fontan operation, a procedure that did not
exclude the RA from high systemic venous pressure. The
majority of patients in this study had their Fontan operation
performed from the late 1970s to the mid 1980s. Thus, the
predominant types of Fontan procedures were RA-PA and
RA-RV connections. The newer variants of the Fontan
operation, such as the TCPC lateral tunnel or extracardiac
Fontan connection, were not widely performed at our major
referring institution until the late 1980s to mid 1990s, and
were not well represented in this patient group. Although
we also found that the AT group had a lower proportion of
TCPC compared with the arrhythmia-free group, it is
unclear whether the association between TCPC and a lower
frequency of AT was a result of the relatively short
follow-up period of these patients or the protection of the
RA from elevated systemic venous pressures (9,10,14,21).
Some have suggested a role for the extracardiac Fontan
connection in view of the observation that atrial incisions
themselves may be partly responsible for late AT (22). A
recent study suggested that lateral tunnel conduit was
associated with the lowest incidence of AT (12).
Atrial size. The mean RA size for the majority of patients
who have had the Fontan operation was larger than normal,
reflecting the elevated RA pressures in these patients. The
mean RA size in Fontan patients who developed AT was
significantly greater than that of the arrhythmia-free group,
suggesting that RA distention contributed to the develop-
ment of AT. In addition, the mean LA size in Fontan
patients who developed AT was significantly larger than
that of the arrhythmia-free group. Because the relation
between LA dilation and the development of atrial fibrilla-
tion has been well documented in patients with acquired
cardiac lesions, it is possible that LA distention also con-
tributed to the development of AT in patients who have had
the Fontan operation (23,24). The enlargement of the LA
could be a consequence of systemic dysfunction or AVVR,
both of which were more prevalent in this study’s arrhyth-
mia group. This relation between LA size and the develop-
ment of AT in patients who have had the Fontan operation
has not been reported previously. The previously described
relation between older age at operation and late AT is
confirmed by our observation that the mean age at the
Fontan procedure was higher in patients who developed AT
than in those who did not (9,12). Older patients who do not
have a Fontan circulation will be subjected to longer periods
of hypoxia and ventricular volume overload, with resultant
ventricular hypertrophy and abnormalities in diastolic fill-
ing. The development of systemic AVVR will result in
further elevations in LA pressure, providing a stimulus for
arrhythmia development.
Heart failure and systemic ventricular dysfunction. Fon-
tan patients who developed AT had a significantly higher
frequency of symptomatic heart failure compared with those
without AT. Although most patients in this study who
developed heart failure did so after their first episode of AT,
the remaining patients developed heart failure without a
documented arrhythmia or before the onset of AT. This
suggests that heart failure can be a precipitant or a conse-
quence of AT in the adult with Fontan physiology.
Cardiac thrombosis. Consistent with other reports, most
of our patients’ thromboemboli originated in the venous
circulation, with the majority of these located either in the
true RA or within the Fontan conduit (25–31). Fontan
patients who developed AT had a significantly higher
frequency of RA thrombus. Twelve of the 14 patients who
developed cardiac thrombus had AT. In nine of these
patients, the cardiac thrombus was diagnosed after the onset
of AT. Although the relation between AT and thrombus
development is presumed to be mediated by increased stasis
within the atria in the setting of diminished cardiac output,
other studies of patients who have had the Fontan operation
have reported the presence of prothrombotic coagulation
abnormalities in protein C, antithrombin III, factor II,
factor I and von Willebrand factor (6,32). Given the high
incidence of AT and thromboembolism in the Fontan
population, routine prophylactic anticoagulation with war-
farin or antiplatelet agents has been suggested, despite the
lack of clinical trials confirming the efficacy of such an
approach (33). The one study examining the efficacy of
prophylactic anticoagulation revealed a frequency of venous
thrombosis of 7%, despite the use of warfarin for three
months in the whole Fontan cohort (34).
Reoperations. The development of arrhythmias was asso-
ciated with an increased frequency of reoperations. This
finding may be explained by the fact that over half of the
operations were for replacement of obstructed Fontan con-
duits. Because arrhythmia development is associated with an
increased frequency of RA thrombus, one could also expect
a higher frequency of conduit replacements.
Pulmonary embolism. The frequency of pulmonary em-
bolism in this study (10%) fell within the range (3% to 17%)
of the few previous reports that examined this outcome
(13,30,35). Although a higher frequency of pulmonary
embolus in patients who develop AT might be expected, in
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this study, the frequency of pulmonary embolism was found
to be similar in both the arrhythmia and arrhythmia-free
groups. It is possible that due to our small sample size, the
study lacked the power to reveal any difference in the
frequency of this clinical event. Patients in the AT group
may have developed fewer pulmonary emboli because more
patients in the AT group were anticoagulated either for the
prevention or diagnosis of RA thrombus.
Mortality. A study published from the Mayo Clinic, with
a mean follow-up of four years, showed a significant number
of late deaths (6 [26%] of 23) after the Fontan operation,
attributable to arrhythmias (36). However, this was not the
finding of our study. Only one of nine late deaths was due
to a presumed arrhythmia, and there was no significant
difference in the mortality rate between the arrhythmia and
arrhythmia-free groups. Our findings are in agreement with
Gewillig et al.’s study (7), which reported that none of their
late deaths (3 of 78) was provoked by an arrhythmia.
Although the lack of a statistically significant difference in
mortality between patients with and those without AT may
be a result of the modest sample size and length of
follow-up after the development of arrhythmias (five years),
it is possible that the mortality impact of AT in adults who
have the Fontan procedure may be different from that of the
pediatric population. For example, early arrhythmias after
the Fontan procedure may be a reflection of baseline or
residual hemodynamic aberrations, which are associated
with a poor prognosis.
Study limitations. This was a retrospective study that
included adult survivors of a childhood procedure who
successfully made the transition from a pediatric to an adult
institution. The sample size is modest, and the study may
lack the power to determine a significant difference in
frequency of pulmonary embolism or mortality between the
two groups in the study. A larger patient sample will also
allow elucidation of possible differences in baseline charac-
teristics between patients presenting with isolated versus
recurrent/chronic arrhythmias. Because routine transesoph-
ageal echocardiography was not performed in patients who
had the Fontan procedure, the incidence of RA thrombus
may have been underestimated in the arrhythmia-free
group. This study may have over-represented the percentage
of patients in whom these clinical events developed, because
patients with symptoms may be more likely to seek their
cardiologist and hence be referred to our center. However,
the referral bias is minimized by the fact that our center is
the main continuity clinic within metropolitan Toronto for
adults who underwent the Fontan operation; also, our
patients are seen annually. A retrospective study such as this
would be unable to assess the frequency of paroxysmal AT,
because the patient’s clinic evaluations were scheduled on an
annual basis.
Clinical implications. Our study demonstrates that AT is
commonly associated with the development of RA throm-
bus. Fontan patients in whom AT develops should be
anticoagulated and screened for atrial thrombus with trans-
esophageal echocardiography. The efficacy of routine anti-
coagulation in patients with Fontan physiology is being
evaluated in an ongoing Canadian multicenter clinical trial.
For patients with refractory arrhythmias, despite pharma-
cologic therapy, surgical revision of a lateral tunnel or
extracardiac Fontan connection, combined with electro-
physiologically guided cryoablation, can be considered. This
approach may decrease the incidence of recurrent AT more
than either technique alone (37).
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